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Objective:
 
 To compare costs of hospitalization for lower
respiratory tract infection (LRTI) in patients who re-
ceived antibiotics before admission to those who did not,
and in patients with and without underlying chronic ob-
structive airways disease (COAD) or diabetes mellitus.
 
Methods:
 
 All hospitalizations in a population of
366,849 residents in Tayside Scotland from 1993 to
1994 were analyzed. Three groups of patients were
identified by primary discharge diagnosis in 1993/94
and previous admissions from 1980 to 1992: 1) acute
exacerbation of COAD; 2) LRTI plus a secondary diag-
nosis of COAD or previous admission with COAD; 3)
LRTI but no secondary COAD or previous admission
with COAD. Setting specific costs were applied (e.g.,
general medicine, intensive care, geriatrics). Dispensed
antibiotic prescribing in the 28 days before admission
was identified from all community pharmacies. Non-
parametric statistical tests were used.
 
Results:
 
 Patients with COAD were more likely to have
 
received antibiotics before admission: COAD (
 
n
 
 
 

 
 893)
49%; COAD 
 

 
 LRTI (
 
n
 
 
 

 
 316) 43%; LRTI only (
 
n
 
 
 

 
822) 33%. Patients who received antibiotics before ad-
mission had lower hospital costs than patients who did
not. Mean total costs per admission: COAD £1604 ver-
sus £1625 (
 
p
 
 
 

 
 .5); COAD 
 

 
 LRTI £2281 versus
£2297 (
 
p
 
 
 

 
 .5); LRTI only £2365 versus £3233; (
 
p
 
 
 

 
.009). Increasing age and diabetes mellitus were associ-
ated with higher hospital costs in all three groups.
 
Conclusion:
 
 Economic models of the value of prevent-
ing hospital admissions for COAD or LRTI will be sub-
ject to case mix bias unless they adjust for age, commu-
nity antibiotic use, and comorbidity.
 
Introduction
 
Lower respiratory tract infection (LRTI) is the
most common community-acquired infection caus-
ing admission to hospital in the UK [1]. These in-
fections are usually treated with parenteral antibi-
otics but parenteral administration is both more
costly and more dangerous than oral administra-
tion [2]. Oral treatment is as effective as parenteral
treatment, provided that the drugs selected are ef-
fective against the pathogens that cause LRTI and
are well absorbed after oral administration [3].
If LRTI can be treated with oral therapy in hos-
pitals, it follows that hospitalization might be
avoided by improving the selection of antibiotic
therapy in the community [4], or by improving
compliance with the drugs prescribed [5]. Other
interventions such as vaccination may also prevent
hospitalization for LRTI [6–9].
The aim of the present study was to provide in-
formation about the costs of hospitalization for
community-acquired LRTI to be used in economic
modeling of the cost-effectiveness of interventions
that might prevent hospitalization, which is the
major cost driver in most healthcare systems.
There are three common sources of bias in health-
care costs: site selection, method of cost alloca-
tion, and case mix [10]. This study was designed
to answer two specific questions about case mix:
1. Do patients who receive antibiotic treatment
before hospital admission have different hospi-
tal costs from those who do not receive treat-
ment?
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2. What is the effect of comorbidity with chronic
obstructive airways disease (COAD) or diabe-
tes on hospital costs for patients admitted with
lower respiratory tract infection?
 
Methods
 
Study Population
 
All residents in Scotland who register with a pri-
mary care doctor are assigned a unique commu-
nity health number that is then used to index all of
their primary and secondary healthcare records.
The subjects for the analysis were drawn from the
population (
 
n
 
 
 

 
 366,849) who were known to be
resident in Tayside from January 1989 to Decem-
ber 1994. The analysis was restricted to adults
aged 40–99 who had emergency admissions to
any of the hospitals providing acute secondary
care in Tayside (Fig. 1).
 
Organization of Hospital Care in Tayside.
 
There
are three providers of acute secondary care in Tay-
side, located in Dundee, Perth, and Brechin. Only
in Dundee are there specialist communicable dis-
eases and respiratory wards.
 
Data Sources
 
Hospital discharge data were obtained from the
Scottish Morbidity Record database 1 (SMR1)
[11]. This database records information about
each hospital discharge from acute hospitals, in-
cluding: date and source of the admission (from
the community or another hospital), the hospital,
the specialty, up to six diagnostic codes, and the
date and destination at discharge (i.e., died or dis-
charged to the community or another hospital).
From 1989 to 1996 the diagnostic codes in SMR1
are from the International Classification of Dis-
ease, version 9 (ICD9) and are further classified
into a primary code (a single code giving the pri-
mary reason for hospitalization) and secondary
codes (all remaining codes) [11]. Community drug
utilization data were obtained from the Tayside
Scripts Facility, which contains data about drugs
dispensed from community pharmacies in Tayside
from 1989 [11]. The TSF database currently holds
records for all antibiotic prescriptions dispensed
from 1993 to 1995 inclusive. Dates of death were
obtained from the Tayside Community Health In-
dex database, which contains information about
all subjects registered with primary care practices
in Tayside [11].
 
Identification of Patients and Comorbidities
 
Lower Respiratory Tract Infection.
 
LRTI was
identified from the SMR1 database by ICD9 codes
466 (acute bronchitis); 480–486 and 487 A (com-
munity acquired pneumonia); 511 (bacterial pleu-
risy); 513 (abscess of the lung); and 514 (hypo-
static pneumonia).
 
Chronic Obstructive Airways Disease.
 
COAD
was identified from the SMR1 database by ICD9
codes 491 (chronic bronchitis) and 496 (other spec-
ified chronic obstructive airways disease).
 
Diabetes Mellitus.
 
Diabetes mellitus was ascer-
tained from the Diabetes Audit and Research in
Tayside Scotland (DARTS) database [12]. DARTS
integrates data from multiple sources (inpatient
episodes, outpatient clinic records, laboratory in-
vestigations, dispensed prescribing, and commu-
nity eye screening) to compile a register of all dia-
betics in Tayside. The DARTS register has been
validated by comparison with primary and sec-
ondary care source records [12].
 
Classification of Patients
 
All hospitalizations in the study population were
identified from February 1993 to December 1994
(January 1993 was used as a screening period for
antibiotic treatment before admission). In addi-
tion, hospitalization from 1989 to 1993 was used
to identify admissions for COAD before the start
of the study period.
Figure 1 Flow chart to show the derivation of the study
population.
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Hospitalizations eligible for analysis between
February 1993 and December 1994 were classi-
fied into three groups:
Group 1: Acute exacerbations of COAD. These
patients had one of the COAD codes as the pri-
mary diagnosis and did not have any LRTI code in
the list of secondary diagnoses.
Group 2: Lower respiratory tract infection and
COAD. These patients had one of the LRTI codes
as the primary diagnosis but either had COAD as
a secondary diagnosis for the same hospitaliza-
tion, or had a previous hospitalization with COAD
as a primary or secondary diagnosis. Patients with
COAD as a primary diagnosis and LRTI as a sec-
ondary diagnosis were also included in this group.
Group 3: Lower respiratory tract infection
only. These patients had one of the LRTI codes as
the primary diagnosis and had no hospitalization
from 1989 to 1994 with COAD as a primary or
secondary code.
 
Prescribing Before Hospital Admission
 
Antibacterial drugs were identified from Chapter
5.1 of the British National Formulary, September
1995. All oral antibacterials were included with
the exception of 5.1.11 (metronidazole or tinida-
zole, drugs used only for treatment of infections
caused by protozoa or anaerobic bacteria) and
5.1.13 (fosfomycin, nitrofurantoin, or hexamine
hippurate, drugs used only for urinary tract infec-
tions). Exposure to oral antibiotics within 28 days
before admission to hospital was determined from
the TSF database.
 
Hospital Costs
 
Estimation of costs of hospitalization was based
on analysis of length of stay in specific specialties
and hospitals. Information about hospital costs in
the financial year 1993–94 was obtained from the
Information and Statistics Division [13]. This pub-
lication includes detailed costs by specialty for ev-
ery hospital in Scotland. Costs are divided into di-
rect patient care (staff costs for medical, nursing
or professions allied to medicine, drugs, investiga-
tions, operations and other therapeutic proce-
dures) and allocated (management, hotel or other
overheads). The perspective of providers or pur-
chasers of secondary care is considered for the
economic analysis.
 
Mortality.
 
Deaths of any citizen of Tayside from
any cause are registered on the Tayside Commu-
nity Health database [11]. Data were available up
to the end of July 1997, providing a minimum of
two years mortality for all patients from date of
entry to the study.
 
Episodes and Periods of Care.
 
Each admission to
a single specialty was termed an episode of care.
Multiple consecutive episodes of care were termed
a period of care. The criteria for linking episodes
of care were the interval between the episodes
(
 

 
24 hours) and the coding for source of admission
and destination at discharge. The first episode al-
ways began with admission from the community
and the last episode always ended with discharge
to the community. However, within a period of care
patients may have been transferred between two
or more clinical specialties.
All statistical analyses were based on the cost
per period of care. This was the sum of costs of
consecutive episodes of care in different hospital
settings (e.g., general medical, geriatric long stay).
The total cost per period of care was calculated
from the number of inpatient days and the average
cost per day for each specific hospital setting. To
investigate the potential confounding effect of
mortality in hospital on length of hospital stay, we
compared the median duration of periods of care
which ended in the death of the patient to those
periods from which the patient was discharged
alive.
 
Base Case and Sensitivity Analysis for Site Se-
lection and Methods Bias.
 
The base case calcu-
lated the cost per period of care from the total cost
per hospital day (direct patient care plus allocated
costs) for each specific hospital setting in Tayside.
Site selection bias was investigated by substituting
the average total cost per hospital day for all equiv-
alent hospital settings in Scotland for the Tayside
hospital cost. Methods bias was investigated by
substituting direct patient care costs for total cost
per hospital day.
 
Statistical Analysis
 
The same patient could appear in Groups 1 and 2
if they had separate admissions with COAD alone
and COAD plus LRTI during the study period. In
contrast, patients in Group 3 could not appear in
either Group 1 or 2 because patients were ex-
cluded from Group 3 if they had a COAD code in
any admission from 1989 to 1994. Comparisons
between groups were therefore only made for
Group 1 versus Group 3 and Group 2 versus
Group 3.
Non-parametric tests were used throughout.
Within-group comparisons for the effect of single
variables (antibiotics and diabetes) on cost were
 336
 
Davey et al.
 
made with the Wilcoxon test. Within-group tests
of the effect of age on cost were made with the
Kruskal–Wallis test. Between-group comparisons
of costs controlling for the effects of other vari-
ables were made with the adjusted Wilcoxon test.
Between-cohort comparisons of mortality were
made with a proportional hazards model and Kap-
lan Meier plots.
 
Results
 
In comparison to patients with COAD (Groups 1
and 2), patients with LRTI only (Group 3) were
less likely to receive antibiotics before admission,
more likely to have diabetes mellitus, and had a
different distribution of age and episodes of care
(Table 1). The median age was highest in Group 3
(76 vs. 74 for Group 2 and 70 for Group 1), but
Group 3 also had the highest proportion of pa-
tients less than 60 years old (Table 1). Patients in
Group 3 were less likely to have episodes of care
in respiratory medicine, but more likely to have
episodes in the intensive care unit, geriatric assess-
ment, and other specialties (Table 1).
Death in hospital occurred much less frequently
in Group 1 compared with Groups 2 or 3. In
Group 1, only 6% of the periods of care ended
with death in hospital, compared to 40% for
Group 2 and 47% for Group 3 (Table 1). In
Group 3 patients who died in hospital had signifi-
cantly longer length of stay than patients who
were discharged alive (median 14 days vs. 9 days,
95% CI of difference between medians 2–6 days;
 
p
 
 
 

 
 .0001 Mann Whitney test). However there
was no significant difference in the other two
groups (12 days vs. 10 days in Group 2 and 8 days
vs. 9 days in Group 1; 
 
p
 
 
 

 
 .2 both groups). The
rate ratio for mortality in the LRTI only cohort
(Group 3) versus the COAD only cohort (Group
1) was 2.0 (95% CI 1.74–2.33) unadjusted for age
or sex and 1.99 (95% CI 1.72–2.31) adjusted for
age and sex.
The cost of hospitalization was lower in pa-
tients who had antibiotics before admission in all
three groups, but the difference was only statisti-
cally significant within Group 3 (Table 2). Costs
of hospitalization were higher for patients with di-
abetes mellitus within all three groups but the dif-
ference was only statistically significant within
Group 3 (Table 2). Costs of hospitalization in-
creased significantly with age in all three groups
(Table 2).
Costs of hospitalization were highest in Group
3 (Table 3). The statistical significance of the dif-
ference between Groups 1 and 3 was not changed
by adjustment for antibiotics, diabetes, and age,
whereas adjustment reduced the statistical signifi-
cance of the difference between Groups 2 and 3
(Table 3). The results were sensitive to site selec-
tion bias. Use of national costs instead of local
costs increased the costs in all three groups and re-
duced the differences in costs between groups. Dif-
ferences between Groups 3 and 1 were no longer
statistically significant with national costs (Table
4). The comparisons between groups were not
sensitive to methods bias. Use of direct patient
 
Table 1
 
Information about case mix
 
Group 1: Acute 
exacerbation of COAD 
only (n 
 

 
 893)
Group 2: Lower 
respiratory tract infection 
and COAD (n 
 

 
 316)
Group 3: Lower 
respiratory tract 
infection only (n 
 

 
 822)
Number % Number % Number %
Received antibiotics before admission 436 49% 136 43% 275 34%
Diabetes mellitus 74 8% 30 9% 84 10%
Age
 

 
60 129 14% 38 12% 136 17%
61–70 319 36% 77 24% 127 15%
71–80 315 35% 126 40% 293 36%
 

 
80 130 15% 75 24% 266 32%
Died in hospital 57 6% 126 40% 384 47%
Total episodes of care 1049 100% 396 100% 1074 100%
Distribution of episodes of care:
General medicine 379 36% 142 36% 448 42%
Respiratory medicine 544 52% 165 42% 213 20%
Communicable diseases 27 3% 11 3% 32 3%
Intensive care unit 24 2% 12 3% 56 5%
Geriatric assessment 42 4% 45 11% 190 18%
Geriatric long stay 4 0% 6 2% 37 3%
Other 29 3% 15 4% 98 9%
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care costs instead of total costs reduced the mean
cost in all three groups but had little effect on the
statistical significance of the differences between
groups (Table 4).
 
Discussion
 
Case Mix Bias
 
There were differences in case mix between the
groups (Table 1) and each of the case mix vari-
ables had a significant effect on costs of hospital-
ization in at least one of the groups (Table 2). Age
was the most important case mix variable, in that
increasing age was associated with a statistically
significant increase in costs of hospitalization in
all groups (Table 2). There is ample evidence to
show the importance of adjusting for age when es-
timating the costs of hospital-acquired infection
[14–16]. Age is also an important determinant of
both mortality and length of stay for patients with
community-acquired pneumonia [17]. It is there-
fore not surprising that our results show that age
is an important determinant of the costs of hospi-
talization in all three cohorts.
Mortality was markedly different between the
groups, both in hospital and following hospital
discharge. Monthly mortality in both the LRTI
only and LRTI 
 

 
 COAD groups was significantly
higher than in the COAD only group in each of
the first four months after admission to hospital
(Fig. 2). Mortality from community-acquired pneu-
monia is usually estimated to be about 20% [18,19].
Our study was confined to patients over the age of
40, which would increase mortality because 97%
of deaths from pneumonia occur in patients over
the age of 65 [17]. Furthermore, even when re-
porting outcome of pneumonia in the elderly, pre-
vious studies have excluded patients with rapidly
fatal underlying disease, excluded deaths that were
not thought to be directly due to pneumonia, and
 
Table 2
 
Influence of case mix variables on mean hospital cost of periods of care (£) within each group. The hospital cost is the 
total cost (direct patient care cost plus allocated cost).
 
Group 1: COAD only Group 2: COAD and LRTI Group 3: LRTI only
Antibiotic £1604 £2281 £2365
No antibiotic £1625 £2297 £3233
P (Wilcoxon) 0.49 0.51 0.009
Diabetic £1660 £2808 £3564
Non-diabetic £1611 £2236 £2872
P (Wilcoxon) 0.18 0.46 0.0365
Age:
 

 
60 £1281 £1059 £2276
61–70 £1597 £2265 £2334
71–80 £1679 £2509 £3298
 

 
80 £1834 £2573 £3181
P (Kruskal-Wallis) 0.0001 0.0008 0.0001
 
Table 3
 
Mean hospital costs (£) per period of care and per patient for episodes of care by specialty. The mean cost per 
patient for episodes of care is the total cost of all episodes of care divided by the number of people in the group. Statistical 
analysis is provided both unadjusted and adjusted for case mix variables. The hospital cost is the total cost (direct patient care 
cost plus allocated cost).
 
Mean cost (£) P (unadjusted)
P (controlling for 
antibiotics, diabetes
and age)
Group 1: 
COAD only
Group 2: 
COAD and LRTI
Group 3: 
LRTI only Gp 1 vs 3 Gp 2 vs 3 Gp 1 vs 3 Gp 2 vs 3
Mean cost per period of care 1615 2290 2943 0.001 0.086 0.001 0.271
Mean cost per patient of episodes 
of care by specialty
General medicine 542 641 773 0.001 0.002 0.001 0.071
Respiratory medicine 649 638 283 0.001 0.001 0.001 0.001
Infectious diseases 138 191 145 0.333 0.752 0.712 0.210
Intensive Care Unit 73 212 295 0.001 0.058 0.018 0.461
Geriatric Assessment 126 456 753 0.001 0.001 0.001 0.009
Geriatric Long Stay 6 35 268 0.001 0.036 0.001 0.154
All Other Units 81 118 425 0.001 0.001 0.001 0.009
 338
 
Davey et al.
 
restricted follow up to the acute hospital setting
[17,20]. Our results show that pneumonia has an
impact on total mortality for at least four months
after diagnosis (Fig. 2).
Prescription of antibiotics before hospitaliza-
tion was associated with lower costs of hospital-
ization in all three groups, and particularly those
with LRTI only. Treatment with antibiotics before
admission could have either a positive or negative
confounding effect on length of hospital stay. Pa-
tients who are hospitalized with lower respiratory
tract infections caused by beta-lactamase–produc-
ing organisms are more likely to have received an-
tibiotics before admission [21]. Our local hospital
antibiotic policy follows national guidelines and
recommends amoxycillin alone for acute exacer-
bations of COAD and amoxycillin plus erythro-
mycin for pneumonia, with or without COAD
[22]. We have previously shown that patients with
acute exacerbations of COAD have a lower rate of
response to amoxycillin if they have received anti-
biotics before admission [22]. Thus, antibiotic
treatment before hospitalization could be associ-
ated with a longer duration of hospitalization if it
is associated with a higher probability of infection
with antibiotic resistant organisms, and hence of
failure to respond to first line antibiotic treatment.
Conversely, antibiotic treatment before hospital
admission was associated with reduced hospital
mortality from community-acquired pneumonia
in a recent study from Italy [23]. This result could
be due to a beneficial effect of antibiotic treatment
before hospital admission. However, it is more
likely that community antibiotic treatment acts as
a marker for patients with less severe illness, be-
cause those with severe illness are admitted straight
Figure 2 Mortality from all causes in the
two years following admission of patients
to hospital with COAD or LRTI.
 
Table 4
 
Sensitivity of between group comparisons to methods bias (total costs vs. direct patient care costs) and site selection 
bias (local costs vs. national costs). The costs are the mean cost per period of care (£).
 
P (controlling for 
antibiotics, diabetes
and age)
Group 1:
COAD only
Group 2: 
COAD and LRTI
Group 3: 
LRTI only Gp 1 vs 3 Gp 2 vs 3
Default: Total costs (direct patient care
 

 
allocated), local 1615 2290 2943 0.001 0.271
Total costs, national 2071 2690 3054 0.105 0.980
Direct patient care costs only, local 927 1315 1661 0.001 0.339
Direct patient care costs, national 1355 1752 1934 0.151 0.995
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to hospital. In the present study community antibi-
otic treatment was associated with shorter duration
of hospital stay, particularly in patients with LRTI
alone.
Comorbidity can also have either a positive or
negative confounding effect on hospital length of
stay [24]. This study investigated the possible con-
founding effect of five selected secondary dis-
charge diagnoses on additional length of hospital
stay due to hospital acquired infection. The five
secondary diagnoses were pulmonary embolism,
renal failure, obesity, diabetes mellitus, and chronic
lung disease. All of these diagnoses had a negative
confounding effect in patients at low risk of infec-
tion but a positive confounding effect in patients
at high risk of infection. Previous studies had as-
sumed that underlying chronic problems would al-
ways have a positive confounding effect on length
of hospital stay. The authors postulated that pa-
tients who also had diabetes mellitus or chronic
lung disease might be admitted to hospital with
mild acute problems, whereas patients without un-
derlying disease would only be admitted with se-
vere acute problems [24]. In the present study dia-
betes mellitus had a positive confounding effect on
length of stay in all three groups, whereas chronic
lung disease had a negative confounding effect in
that length of stay and costs were lower in Group
2 than Group 3.
 
Site Selection Bias
 
Comparison of costs of hospitalization between
countries reveals striking differences. For example
the costs of hospitalization for invasive infections
caused by Haemophilus influenzae Type B have
been shown to vary almost tenfold across seven
countries. In ascending order, the costs per case
were $1,121 in Chile, $2,608 in Israel, $4,298 in
the UK, $4,767 in Finland, $5,048 in Switzerland,
$5,495 in Australia, and $10,000 in the USA [6].
Our results are influenced by site selection in that
differences between Group 1 (COAD only) and
Group 3 (LRTI only) were no longer statistically
significant when national costs were substituted
for local costs (Table 4). The most likely explana-
tion is the relatively low local costs of Respiratory
Medicine (£97 per day compared with a national
average of £158 per day, Table 5). Respiratory
Medicine accounted for a much higher proportion
of periods of care in Group 1 compared with
Group 3 (52% vs. 20%; Table 1).
 
Methods Bias
 
Much of the literature on costs of hospitalization
is concerned with the economic impact of earlier
discharge from hospital. In this context, use of av-
erage costs is misleading, particularly for surgical
patients [25]. This is because the distribution of
hospital costs is uneven over time and is usually
higher in the first few days of an admission [26].
However, the aim of our study was to provide es-
timates of the value of preventing a hospital ad-
mission, rather than shortening length of hospital
stay. In this context the use of average costs may
be a reasonable estimate of the marginal cost per
case.
Our estimates of the cost per period of care are
substantially higher than the estimates of the cost
per case provided by Information and Statistics
Division (ISD) [27]. For example, our cost per pe-
riod of care ranged from £1611 for a nondiabetic
patient with COAD to £3564 for a diabetic pa-
tient with LRTI (Table 2). The ISD’s quoted aver-
age cost per case for General Medicine and Respi-
ratory Medicine in Dundee are only £1219 and
£1527, respectively [27]. This is because the ISD
figures are based on the average cost of an episode
of care, whereas our data show that periods of
care are often composed of more than one episode
of care in different settings (Table 1).
The contribution of direct patient care to total
costs was not constant across specialties at the
same site, or between specialties on different sites
(Table 5). In general direct patient care accounted
 
Table 5
 
Costs per day (£) by specialty and site. Data from Information and Statistics Division [13]
 
Local, Dundee Local, Perth Local, Angus National
Total Direct Ratio* Total Direct Ratio* Total Direct Ratio* Total Direct Ratio*
General medicine 175 120 69% 150 75 50% 143 85 59% 178 110 62%
Respiratory 97 54 56% NA NA NA NA NA NA 158 102 65%
Infectious diseases 447 304 68% NA NA NA NA NA NA 310 196 63%
Intensive care 901 624 69% 859 537 63% 244 168 69% 774 574 74%
Geriatric assessment 145 88 61% 122 52 43% 108 52 48% 120 69 58%
Geriatric long stay 79 39 49% 120 52 43% 130 78 60% 98 52 53%
Other 243 158 65% 304 203 67% 231 158 68% 219 141 64%
 
*Ratio 
 

 
 Direct costs/total costs
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for a higher proportion of total costs in Intensive
Care than in Geriatric Long Stay (74% vs. 53%
for National figures). Nonetheless, substituting di-
rect patient care costs for total costs did not influ-
ence the conclusions of this study (Table 4).
 
Limitations of the Study
 
Ascertainment of COAD was based on hospital
discharge diagnoses from 1980 to 1994. The pop-
ulation of Tayside is relatively stable in that 
 

 
5%
of the population move in or out of the area in a
year [11]. Nonetheless, the use of previous hospi-
tal discharge codes for ascertainment may have
caused some misclassification bias if patients had
never been admitted with COAD in the past, or
had been admitted previously to a hospital outside
the Tayside area. Either of these possibilities could
result in patients with COAD being misclassified
in the LRTI-only cohort. However, this would
bias the results towards the null hypothesis (that
there is no difference between Group 1 (COAD
only) and Group 3 (LRTI only)).
The indication for antibiotic prescription in the
28 days before hospital admission is not known.
The finding of lower costs in patients who re-
ceived antibiotics before admission may be ex-
plained by patients with less severe illness being
treated in the community before admission to hos-
pital. If this is true then inclusion of data about
antibiotic prescribing for indications other than
respiratory tract infection would bias the results
towards the null hypothesis (that there is no influ-
ence of community antibiotic treatment on costs
of hospitalization).
An intervention that does prevent hospital ad-
missions is unlikely to result in equivalent cash
savings to the hospital and will not necessarily im-
prove patient throughput [28]. Moreover, such an
intervention is likely to increase costs to the pri-
mary care sector as well as to the patient’s family
or carergivers and may result in loss of welfare to
the patient [28]. Consequently our results provide
an estimate of the maximum value to the second-
ary care services of preventing a hospital admis-
sion with COAD or LRTI.
 
Implications of the Study
 
Case mix was the most important source of bias
and our results suggest that a wide range of costs
(£1281–£3564) should be used in sensitivity anal-
ysis of the value of preventing hospitalization with
COAD or LRTI. Within the UK site selection is
likely to be a much less important source of bias
and any variation is likely to be encompassed
within the range of costs used to allow for case
mix bias. However, site selection bias is likely to
be more important for international economic
models [6]. Overall our data are likely to overesti-
mate the marginal cost of hospitalization with
COAD or LRTI. These data may be used in pre-
liminary economic modeling of the impact of in-
terventions that reduce hospitalization. However,
randomized trials will be required to minimize
bias and provide convincing evidence of cost-
effectiveness.
 
The study was funded by a grant from Glaxo Wellcome
Research and Development. We would like to thank Dr
Peter Donnan for performing the proportional hazards
analysis of mortality.
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